TIDMEKF
RNS Number : 0562A
EKF Diagnostics Holdings PLC
31 January 2022
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Non-executive Directorate Change
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed
point-of-care business , announces the appointment of Jenny Winter
as Non-executive Director ("NED"), effective on 1 February 2022. At
the same time Carl Contadini, Non-executive Director, will stand
down from the Board.
Jenny has over 20 years' experience across a broad variety of
healthcare organisations ranging from small not-for-profit
companies to large corporates. Jenny is currently Chief Executive
Officer of AIM listed Animalcare Group plc (AIM: ANCR) where she is
successfully executing on the business's long-term growth strategy,
as reflected in the recently announced strong full year trading
performance against a backdrop of very challenging market
conditions.
Jenny has a science-led career spanning R&D, clinical
research, strategic product development and commercial growth
across various aspects of the healthcare industry. Before joining
Animalcare Group plc in October 2018, Jenny was Vice President of
Respiratory products - Global Supply Chain and Strategy at
AstraZeneca, a position she held from 2015. Other roles at
AstraZeneca included Vice President Cardiology - Global Product and
Portfolio Strategy, Commercial Director - Eastern Europe, Marketing
Company President Hungary, where she led a major change programme
to drive future success, and Global Vice President, Group Public
Affairs.
Jenny has also been CEO of the charity Barretstown, transforming
it into a successful leading charity which provides therapeutic
recreation programmes for children and their families affected by
serious illness, as well as virtual school and hospital outreach
activities. Her work at the charity resulted in her being invited
by Barretstown board member Dermot Gleeson, Chairman of Allied
Irish Bank, to join the Board of the bank as a Non-executive
Director, a role she held from 2004 to 2010.
Jenny has a BSc in Physiology and Pharmacology from the
University of Southampton.
Christopher Mills, Chairman of EKF, commented:
"I would like to thank Carl for his valuable contribution to the
Board over the last five-and-a-half years. Carl has provided sound
guidance to the Executive and operational teams as they've executed
a successful growth strategy, reflected in the positive trading
update and upgraded year-end guidance provided last week.
"We are also delighted to welcome Jenny to the Board. I have no
doubt that Jenny will bring a lot to the table in terms of her
scientific background, commercial knowledge within the healthcare
sector and her experience with AIM listed companies as they
successfully deliver against long-term growth strategies. We look
forward to working with her and benefitting from her
expertise."
Additional disclosures relating the appointment of Jenny Winter
to the EKF Board are included below.
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Christopher Mills, Non-Executive Chairman Tel: +44 (0)29 2071 0570
Mike Salter, CEO
Marc Davies, CFO
Singer Capital Markets (Nominated Adviser & Tel: +44 ( 0)20 7496 3000
Joint Broker)
Aubrey Powell / George Tzimas / Tom
Salvesen
Investec Bank plc (Joint Broker) Tel: +44 (0)20 7597 4000
Gary Clarence / Daniel Adams / Ben
Farrow
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Applegarth Mob: +44 (0)7980 541 893 / +44 (0)7584 391
303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is a leading point-of-care diagnostics and central
laboratory assay manufacturer with an estimated 80,000 hemoglobin,
hematocrit, HbA1c, glucose and lactate analysers in regular use
across more than 100 countries. EKF specialises in developing tests
for use in anemia and diabetes diagnosis and management, as well as
providing a portfolio of reagents for use in clinical chemistry
analysers.
EKF specialises in the development, production and worldwide
distribution of point-of-care analyzers and clinical chemistry
reagents for use in hospital and research laboratories, doctor's
offices, blood banks and for in-field anaemia screening programmes.
EKF is also a bulk manufacturer of enzymes and has custom
manufacturing facilities across sites in the US, UK and Europe for
a variety of life science products. Driven by customer demand EKF
has invested significantly in increasing the Company's fermentation
capacity. The Company's capabilities and capacity in contract
manufacturing for sample collection, tests and test kits have seen
dramatic growth following strong demand for during the COVID-19
pandemic, and these income streams are now being diversified for
application to other non-COVID areas of diagnostic testing,
molecular disease and forensic test manufacture.
In May 2021, EKF outlined its strategy through to 2024 for
delivering additional growth. As well as the growth expected in
Contract Manufacturing across Life Sciences, molecular diagnostics
and other applications, the Company expects to leverage existing
distribution channels for organic growth, both in the core business
and from additional products to expand the core range, but also
through executing earnings enhancing acquisitions and delivering
further value creating investments associated with the preferred
partnership agreement with Mount Sinai Innovation Partners.
In October 2021, EKF completed the acquisition of Advanced
Diagnostic Laboratory LLC, a Texas based testing laboratory
certified under the Clinical Laboratory Improvement Amendments
("CLIA") for high complexity testing. The laboratory provides
testing for a variety of clinical, forensic and microbiological
sample types using a range of analytical techniques. This
acquisition positions EKF as a leading 'one stop' provider of
diagnostic products and services from sample collection to
results.
Additional Disclosures Required under the AIM Rules for
Companies
Jennifer Ann Julia Winter (aged 62) has held the following
directorship or partnerships in the past five years:
Current directorships and partnerships:
Animalcare Group PLC
Animalcare Ltd (subsidiary of Animalcare Group PLC)
Identicare Ltd (subsidiary of Animalcare Group PLC)
Previous directorships and partnerships held in the past five
years:
Oxford Genetics Ltd
Jenny does not hold any ordinary shares in EKF.
Save as disclosed above, there is no further information to be
disclosed in respect of the above appointment pursuant to Rule 17
and Schedule 2 paragraph (g) of the AIM Rules for Companies.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOASEAFFUEESELF
(END) Dow Jones Newswires
January 31, 2022 01:59 ET (06:59 GMT)
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024